Developmental basis for filamin-A-associated myxomatous mitral valve disease
Open Access
- 25 July 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 96 (1) , 109-119
Abstract
We hypothesized that the structure and function of the mature valves is largely dependent upon how these tissues are built during development, and defects in how the valves are built can lead to the pathological progression of a disease phenotype. Thus, we sought to uncover potential developmental origins and mechanistic underpinnings causal to myxomatous mitral valve disease. We focus on how filamin-A, a cytoskeletal binding protein with strong links to human myxomatous valve disease, can function as a regulatory interface to control proper mitral valve development. Filamin-A-deficient mice exhibit abnormally enlarged mitral valves during foetal life, which progresses to a myxomatous phenotype by 2 months of age. Through expression studies, in silico modelling, 3D morphometry, biochemical studies, and 3D matrix assays, we demonstrate that the inception of the valve disease occurs during foetal life and can be attributed, in part, to a deficiency of interstitial cells to efficiently organize the extracellular matrix (ECM). This ECM organization during foetal valve gestation is due, in part, to molecular interactions between filamin-A, serotonin, and the cross-linking enzyme, transglutaminase-2 (TG2). Pharmacological and genetic perturbations that inhibit serotonin-TG2-filamin-A interactions lead to impaired ECM remodelling and engender progression to a myxomatous valve phenotype. These findings illustrate a molecular mechanism by which valve interstitial cells, through a serotonin, TG, and filamin-A pathway, regulate matrix organization during foetal valve development. Additionally, these data indicate that disrupting key regulatory interactions during valve development can set the stage for the generation of postnatal myxomatous valve disease.Keywords
This publication has 41 references indexed in Scilit:
- Expression of the familial cardiac valvular dystrophy gene, filamin‐A, during heart morphogenesisDevelopmental Dynamics, 2010
- Developmental basis of adult cardiovascular diseasesAnnals of the New York Academy of Sciences, 2010
- Fenfluramine Disrupts the Mitral Valve Interstitial Cell Response to SerotoninThe American Journal of Pathology, 2009
- Serotonylation of Vascular Proteins Important to ContractionPLOS ONE, 2009
- Periostin regulates atrioventricular valve maturationDevelopmental Biology, 2008
- Developmental effects of SSRIs: lessons learned from animal studiesInternational Journal of Developmental Neuroscience, 2007
- Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinaseDevelopmental Biology, 2007
- Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissuesJournal of Cellular Biochemistry, 2007
- Filamin A (FLNA) is required for cell–cell contact in vascular development and cardiac morphogenesisProceedings of the National Academy of Sciences, 2006
- IntegrinsCell, 2002